more often presented with prior percutaneous or surgical revascularization (46.0% vs. 37%, p¼0.003). Of the 365 diabetics, 101 (27.6%) were ITDM. ITDM patients were more often female (35.6% vs. 21.6, p¼0.006) and with a history of prior MI (50.0% vs. 31.8%, p¼0.001) compared to NITDM. At 12-months follow-up, the cumulative incidence of cardiac death, TLR and MI in patients with diabetes was comparable to that of non-diabetics (3.7% vs. 5.0%, p¼0.417). The ITDM patients demonstrated a higher, but non-significant, incidence of the composite end-point compared to NITDM (4.4% vs. 3.4%, p¼0.70). The incidence of definite/probable stent thrombosis was similar between diabetics (2/365; 0.5%) and non diabetics (5/ 851; 0.6%). Conclusions: In this multicenter registry of patients suitable for PCI, the R-ZES resulted as safe and effective in diabetic and non-diabetic patients at 1-year follow-up. Among diabetics, patients with ITDM are associated with a higher, but not significant, incidence of adverse events than patients with NITDM.
TCT-211
Stenting Results: Patients baseline characteristics were well balanced between groups. At 9 months, in-stent late lumen loss in PCB+BMS were comparable and non-inferior to PES (0.21AE0.5 vs. 0.30AE0.7mm respectively, pnon-inf<0.05). Clinically, the incidence of MACCE (7.0 vs. 6.9%, HR¼1 95%CI:0.3-2.8; p¼0.99), comprising of occurrence of myocardial infarction (4.9 vs. 3.0% HR¼1.62 95%CI:0.4-6.5; p¼0.32), target lesion revascularization (6.9 vs. 5.0%, HR¼1.42 95%CI: 0.4-4.4; p¼0.54) and stent thrombosis (ST: 5.9 vs. 3.8% HR¼2.01 95%CI: 0,5 to 7,4) was similar between PCB+BMS and PES respectively. In PCB+BMS when compared to PES most ST occurred early (5.0 vs. 1.0%; p¼0.10), whereas in PES -late (0.9 vs. 2.8% p¼0.18). There were no deaths or cerebro-vascular accidents in both groups.
Conclusions: Revascularization strategy with PCB+BMS is an alternative to PES with regard to neointimal hyperplasia, however the incidence of early ST raises safety concerns. Fortis Escorts Heart Institute, Okhla Road, New Delhi 110025 (India), New Delhi, India Background: The novel BioMime drug-eluting stent (Meril Life Sciences Pvt. Ltd., Gujarat, India) incorporates a L605 cobalt-chromium metallic platform that combines ultra-thin struts (65mm) with hybrid cell design and a bioabsorbable co-polymer (PLLA/PLGA) formulation (2mm thickness) which carries and releases sirolimus in a dosage of 1.25mg per mm2 of stent surface area. Our objective was to report the angiographic findings of the BioMime sirolimus-eluting stents (SES) tested in the meriT-1 and -2 clinical trials. Methods: 280 pts with 385 de novo lesions located in native vessels were prospectively enrolled in 2 non-randomized studies in India, including the first-in-man, single center meriT-1 trial (30 patients/lesions) and the subsequent multicenter meriT-2 trial (250 pts/355 lesions). Angiographic follow-up was assigned at 8 months. QCA analysis was performed at an independent angiographic core lab. Results: LAD was the target vessel in 47%, 16.4% had significant calcium, 78.4% were eccentric, 4.9% had ulcer and pre-TIMI flow 3 was found in 87.5%. Most lesions were classified as highly complex (type B2/C in 74.8%). Predilatation was performed in 91%, the study stent was implanted in 100%, an additional study stent was implanted in 6%, and 60% had postdilatation; also, final TIMI 3 flow was achieved in 99.5%. QCA results are shown in the Table. Binary restenosis was found in 5.7% (4.5% in-stent) including focal pattern (type-I) in most cases (4.8%).
Conclusions:
In this subanalysis of the combined meriT-1 and -2 trials, the novel BioMime SES demonstrated efficacy in the treatment of complex de novo coronary lesions, as demonstrated by the relatively low median in-stent late lumen loss (a surrogate of neointimal hyperplasia) at 8-month angiographic follow-up (87%). In addition, in-stent binary restenosis was low (<5%) and associated with focal pattern in the majority of cases. 
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